Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome

被引：398

作者：

Bittner, Vera A. ^{[1
]}

Szarek, Michael ^{[2
]}

Aylward, Philip E. ^{[3
,30
]}

Bhatt, Deepak L. ^{[4
,5
]}

Diaz, Rafael ^{[6
]}

Edelberg, Jay M. ^{[7
]}

Fras, Zlatko ^{[8
,9
,74
,75
]}

Goodman, Shaun G. ^{[10
,11
]}

Halvorsen, Sigrun ^{[12
,13
,64
]}

Hanotin, Corinne ^{[14
]}

Harrington, Robert A. ^{[15
]}

Jukema, J. Wouter ^{[16
]}

Loizeau, Virginie ^{[14
]}

Moriarty, Patrick M. ^{[17
,87
,1138
]}

Moryusef, Angele ^{[7
]}

Pordy, Robert ^{[18
]}

Roe, Matthew T. ^{[19
,20
]}

Sinnaeve, Peter ^{[21
,22
,32
]}

Tsimikas, Sotirios ^{[23
]}

Vogel, Robert ^{[24
,88
]}

White, Harvey D. ^{[25
]}

Zahger, Doron ^{[26
,52
]}

Zeiher, Andreas M. ^{[27
]}

Steg, Gabriel ^{[28
,29
]}

Schwartz, Gregory G. ^{[24
]}

Aylward, Philip E. ^{[3
,30
]}

Drexel, Heinz ^{[31
,173
]}

Sinnaeve, Peter ^{[21
,22
,32
]}

Dilic, Mirza ^{[33
]}

Lopes, Renato D. ^{[1
,96
,238
]}

Gotcheva, Nina N. ^{[34
,254
]}

Prieto, Juan-Carlos ^{[35
,299
]}

Yong, Huo ^{[36
]}

Lopez-Jaramillo, Patricio ^{[37
]}

Pecin, Ivan ^{[38
]}

Reiner, Zeljko ^{[39
]}

Ostadal, Petr ^{[40
,401
]}

Poulsen, Steen Hvitfeldt ^{[41
]}

Viigimaa, Margus ^{[42
]}

Nieminen, Markku S. ^{[43
]}

Danchin, Nicolas ^{[44
]}

Chumburidze, Vakhtang ^{[45
]}

Marx, Nikolaus ^{[46
,470
]}

Liberopoulos, Evangelos ^{[47
,493
]}

Montenegro Valdovinos, Pablo Carlos ^{[48
]}

Tse, Hung-Fat ^{[49
]}

Kiss, Robert Gabor ^{[50
,507
]}

Xavier, Denis ^{[51
]}

Zahger, Doron ^{[26
,52
]}

Valgimigli, Marco ^{[53
]}

机构：

[1] Univ Alabama Birmingham, Div Cardiovasc Dis, Birmingham, AL USA

[2] SUNY, Downstate Sch Publ Hlth, Brooklyn, NY USA

[3] Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[4] Brigham & Womens Hosp, Heart & Vasc Ctr, 75 Francis St, Boston, MA 02115 USA

[5] Harvard Med Sch, Boston, MA 02115 USA

[6] Inst Cardiovasc Rosario, Estudios Cardiol Latinoamer, Rosario, Argentina

[7] Sanofi, Bridgewater, MA USA

[8] Univ Med Ctr Ljubljana, Prevent Cardiol Unit, Div Med, Dept Vasc Med, Ljubljana, Slovenia

[9] Univ Ljubljana, Med Fac, Ljubljana, Slovenia

[10] Univ Alberta, Canadian VIGOUR Ctr, Edmonton, AB, Canada

[11] Univ Toronto, St Michaels Hosp, Toronto, ON, Canada

[12] Oslo Univ Hosp, Dept Cardiol, Oslo, Norway

[13] Univ Oslo, Oslo, Norway

[14] Sanofi, Paris, France

[15] Stanford Univ, Dept Med, Stanford Ctr Clin Res, Stanford, CA 94305 USA

[16] Leiden Univ, Med Ctr, Dept Cardiol, Leiden, Netherlands

[17] Univ Kansas, Med Ctr, Div Clin Pharmacol, Kansas City, KS 66103 USA

[18] Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA

[19] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA

[20] Duke Univ, Sch Med, Dept Med, Div Cardiol, Durham, NC 27706 USA

[21] Univ Hosp Leuven, Dept Cardiovasc Med, Leuven, Belgium

[22] Univ Leuven, Leuven, Belgium

[23] Univ Calif San Diego, Div Cardiovasc Med, La Jolla, CA 92093 USA

[24] Univ Colorado, Div Cardiol, Sch Med, Aurora, CO USA

[25] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand

[26] Ben Gurion Univ Negev, Soroka Univ Med Ctr, Fac Hlth Sci, Beer Sheva, Israel

[27] Goethe Univ, Dept Med 3, Frankfurt, Germany

[28] Univ Paris, Hop Bichat, AP HP, FACT,INSERM,U1148, Paris, France

[29] Imperial Coll, Natl Heart & Lung Inst, Royal Brompton Hosp, London, England

[30] Flinders Univ & Med Ctr, South Australian Hlth & Med Res Inst, Adelaide, SA, Australia

[31] Landeskrankenhaus Feldkirch, Feldkirch, Austria

[32] UZ Leuven, Leuven, Belgium

[33] Univ Clin Ctr Sarajevo, Sarajevo, Bosnia & Herceg

[34] MHAT Natl Cardiol Hosp EAD, Sofia, Bulgaria

[35] Hosp Clin Univ Chile, Santiago, Chile

[36] Peking Univ First Hosp, Beijing, Peoples R China

[37] Fdn Oftalmol Santander FOSCAL, Floridablanca, Colombia

[38] Univ Zagreb, Univ Hosp Ctr Zagreb, Zagreb Sch Med, Zagreb, Croatia

[39] Univ Zagreb, Univ Hosp Ctr Zagreb, Sch Med, Zagreb, Croatia

[40] Na Homolce Hosp, Prague, Czech Republic

[41] Aarhus Univ Hosp Skejby, Aarhus N, Denmark

[42] SA Pohja Eesti Reg Haigla, Tallinn, Estonia

[43] HUCH, Div Cardiol, Heart & Lung Ctr, Helsinki, Finland

[44] FACT, Hop Europeen Georges Pompidou, Paris, France

[45] Chapidze Emergency Cardiol Ctr, Tbilisi, Georgia

[46] Univ Klinikum Aachen, Aachen, Germany

[47] Univ Gen Hosp Ioannina, Ioannina, Greece

[48] Clin Privada, Unidad Diagnost Cardiol, Guatemala City, Guatemala

[49] Univ Hong Kong, Queen Mary Hosp, Hong Kong, Peoples R China

[50] Magyar Honvedseg Egeszsegugyi Kozpont, Budapest, Hungary

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2020年 / 75卷 / 02期

关键词：

acute coronary syndromes; alirocumab; low-density lipoprotein cholesterol; major adverse cardiovascular events; proprotein convertase subtilisin/kexin type 9 inhibition; REDUCING LIPIDS; EFFICACY; DISEASE; SAFETY; CHOLESTEROL; NIACIN;

D O I：

10.1016/j.jacc.2019.10.057

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BACKGROUND Lipoprotein(a) concentration is associated with cardiovascular events. Alirocumab, a proprotein convertase subtilisin/kexin type 9 inhibitor, lowers lipoprotein(a) and low-density lipoprotein cholesterol (LDL-C). OBJECTIVES A pre-specified analysis of the placebo-controlled ODYSSEY Outcomes trial in patients with recent acute coronary syndrome (ACS) determined whether alirocumab-induced changes in lipoprotein(a) and LDL-C independently predicted major adverse cardiovascular events (MACE). METHODS One to 12 months after ACS, 18,924 patients on high-intensity statin therapy were randomized to alirocumab or placebo and followed for 2.8 years (median). Lipoprotein(a) was measured at randomization and 4 and 12 months thereafter. The primary MACE outcome was coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or hospitalization for unstable angina. RESULTS Baseline lipoprotein(a) levels (median: 21.2 mg/dl; interquartile range [IQR]: 6.7 to 59.6 mg/dl) and LDL-C [corrected for cholesterol content in lipoprotein(a)] predicted MACE. Alirocumab reduced lipoprotein(a) by 5.0 mg/dl (IQR: 0 to 13.5 mg/dl), corrected LDL-C by 51.1 mg/dl (IQR: 33.7 to 67.2 mg/dl), and reduced the risk of MACE (hazard ratio [HR]: 0.85; 95% confidence interval [CI]: 0.78 to 0.93). Alirocumab-induced reductions of lipoprotein(a) and corrected LDL-C independently predicted lower risk of MACE, after adjustment for baseline concentrations of both lipoproteins and demographic and clinical characteristics. A 1-mg/dl reduction in lipoprotein(a) with alirocumab was associated with a HR of 0.994 (95% CI: 0.990 to 0.999; p = 0.0081). CONCLUSIONS Baseline lipoprotein(a) and corrected LDL-C levels and their reductions by alirocumab predicted the risk of MACE after recent ACS. Lipoprotein(a) lowering by alirocumab is an independent contributor to MACE reduction, which suggests that lipoprotein(a) should be an independent treatment target after ACS. (ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; NCT01663402) (C) 2020 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.

引用

页码：133 / 144

页数：12

共 50 条

[21] Drinking patterns of alcohol and risk of major adverse cardiovascular events after an acute coronary syndrome
Tessitore, Elena
Branca, Mattia
Heg, Dik
Nanchen, David
Auer, Reto
Raeber, Lorenz
Klingenberg, Roland
Windecker, Stephan
Luescher, Thomas F.
Carballo, Sebastian
Matter, Christian M.
Gmel, Gerhard
Mukamal, Kenneth J.
Rodondi, Nicolas
Carballo, David
Mach, Francois
Gencer, Baris
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2024, 31 (07) : 845 - 855
[22] Lipoprotein(a) reductions from PCSK9 inhibition and major adverse cardiovascular events: Pooled analysis of alirocumab phase 3 trials
Ray, Kausik K.
Vallejo-Vaz, Antonio J.
Ginsberg, Henry N.
Davidson, Michael H.
Louie, Michael J.
Bujas-Bobanovic, Maja
Minini, Pascal
Eckel, Robert H.
Cannon, Christopher P.
ATHEROSCLEROSIS, 2019, 288 : 194 - 202
[23] High Remnant Lipoprotein Predicts Recurrent Cardiovascular Events on Statin Treatment After Acute Coronary Syndrome
Si Van Nguyen
Nakamura, Takamitsu
Kugiyama, Kiyotaka
CIRCULATION JOURNAL, 2014, 78 (10) : 2492 - 2500
[24] Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab
Landmesser, Ulf
McGinniss, Jennifer
Steg, Ph Gabriel
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Dilic, Mirza
Goodman, Shaun G.
Jukema, J. Wouter
Loy, Megan
Pecin, Ivan
Pordy, Robert
Poulsen, Steen H.
Szarek, Michael
White, Harvey D.
Schwartz, Gregory G.
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2022, 29 (14) : 1842 - 1851
[25] Risk factors for major adverse cardiovascular events after the first acute coronary syndrome
Okkonen, Marjo
Havulinna, Aki S.
Ukkola, Olavi
Huikuri, Heikki
Pietila, Arto
Koukkunen, Heli
Lehto, Seppo
Mustonen, Juha
Ketonen, Matti
Airaksinen, Juhani
Kesaniemi, Y. Antero
Salomaa, Veikko
ANNALS OF MEDICINE, 2021, 53 (01) : 817 - 823
[26] Effect of alirocumab on cataracts in patients with acute coronary syndromes
Gaspard Suc
Gregory G. Schwartz
Shaun G. Goodman
J. Wouter Jukema
Garen Manvelian
Yann Poulouin
Robert Pordy
Michel Scemama
Michael Szarek
Ph. Gabriel Steg
BMC Ophthalmology, 23
[27] Effect of Alirocumab on Incidence of Atrial Fibrillation After Acute Coronary Syndromes: Insights from the ODYSSEY OUTCOMES Trial
Lopes, Renato D.
Guimaraes, Patr Icia O.
Schwartz, Gregory G.
Bhatt, Deepak L.
Bittner, Vera A.
Budaj, Andrzej
Dalby, Anthony J.
Diaz, Rafael
Goodman, Shaun G.
Harrington, Robert A.
Jukema, J. Wouter
Kiss, Robert Gabor
Loy, Megan
Pordy, Robert
Poulouin, Yann
Szarek, Michael
White, Harvey D.
Steg, Philippe Gabriel
AMERICAN JOURNAL OF MEDICINE, 2022, 135 (07) : 915 - 918
[28] Association between Lipoprotein (a) level on admission and the incidence of subsequent cardiovascular events in patients with acute coronary syndrome
Zhou, Jingmin
Cui, Xiaotong
Jin, Xuejuan
Zhou, Jun
Fu, Mingqiang
Zhong, Chunlin
Sun, Aijun
Hu, Kai
Fu, Michael
Ge, Junbo
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2012, 158 (03) : 464 - 466
[29] Rationale and design of MultiSELECt: A European Multicenter Study on the Effect of Lipoprotein(a) Elimination by lipoprotein apheresis on Cardiovascular outcomes
Hohenstein, Bernd
Julius, Ulrich
Lansberg, Peter
Jaeger, Beate
Mellwig, Klaus-Peter
Weiss, Norbert
Graehlert, Xina
Roeder, Ingo
Ramlow, Wolfgang
ATHEROSCLEROSIS SUPPLEMENTS, 2017, 30 : 180 - 186
[30] Alirocumab in Patients With Polyvascular Disease and Recent Acute Coronary Syndrome ODYSSEY OUTCOMES Trial
Jukema, J. Wouter
Szarek, Michael
Zijlstra, Laurien E.
de Silva, H. Asita
Bhatt, Deepak L.
Bittner, Vera A.
Diaz, Rafael
Edelberg, Jay M.
Goodman, Shaun G.
Hanotin, Corinne
Harrington, Robert A.
Karpov, Yuri
Moryusef, Angle
Pordy, Robert
Prieto, Juan C.
Roe, Matthew T.
White, Harvey D.
Zeiher, Andreas M.
Schwartz, Gregory G.
Steg, P. Gabriel
Tricoci, Pierluigi
Mahaffey, Kenneth W.
Lecorps, Guillaume
Moryusef, Angele
Pordy, Robert
Sasiela, William J.
Tamby, Jean-Francois
Aylward, Philip E.
Drexel, Heinz
Sinnaeve, Peter
Dilic, Mirza
Gotcheva, Nina N.
Goodman, Shaun G.
Prieto, Juan-Carlos
Yong, Huo
Lopez-Jaramillo, Patricio
Pecin, Ivan
Reiner, Zeljko
Ostadal, Petr
Poulsen, Steen Hvitfeldt
Viigimaa, Margus
Nieminen, Markku S.
Danchin, Nicolas
Chumburidze, Vakhtang
Marx, Nikolaus
Liberopoulos, Evangelos
Valdovinos, Pablo Carlos Montenegro
Tse, Hung-Fat
Kiss, Robert Gabor
Xavier, Denis
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 74 (09) : 1167 - 1176

← 1 2 3 4 5 →